

# CITATION REPORT

List of articles citing

Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study

DOI: 10.1002/cncr.22904  
Cancer, 2007, 110, 1376-84.

**Source:** <https://exaly.com/paper-pdf/42622984/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
346	Éducation thérapeutique. <b>2006</b> , 1, 1-6		
345	Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. <b>2008</b> , 61, 903-9		196
344	Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy. <b>2008</b> , 9, 191-203		44
343	Long-term follow-up of renal function after high-dose methotrexate treatment in children. <b>2008</b> , 51, 535-9		18
342	Estimation of renal function -- what is appropriate in cancer patients?. <b>2008</b> , 20, 721-6		23
341	Ovarian cancer in older women. <b>2008</b> , 35, 582-9		18
340	Contrast safety in the cancer patient: preventing contrast-induced nephropathy. <b>2008</b> , 8 Spec No A, S124-7		11
339	Chemotherapy for the Older Adult with Cancer. <b>2009</b> , 201-261		
338	Drug management of prostate cancer: prevalence and consequences of renal insufficiency. <b>2009</b> , 7, E83-9		19
337	Recommandations pour la pratique clinique: Nice, Saint-Paul de Vence 2009 « cancers du sein » et « soins de support ». <b>2009</b> , 11, 612-793		2
336	Lung cancer and renal insufficiency: prevalence and anticancer drug issues. <b>2009</b> , 187, 69-74		34
335	Bladder cancer. <b>2009</b> , 10, 205-15		27
334	Renal toxicity of targeted therapies. <b>2009</b> , 4, 121-33		41
333	Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. <b>2009</b> , 70, 124-33		34
332	Nephrotoxicity of cancer treatment in children. <b>2010</b> , 4, 519-538		9
331	Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. <b>2010</b> , 124, 745-53		37
330	Cancer and renal insufficiency results of the BIRMA study. <b>2010</b> , 103, 1815-21		120

329	Management of ovarian and endometrial cancer in older adults. 201-218		1
328	Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. <b>2010</b> , 50, 472-81		58
327	Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin. <b>2010</b> , 16, 113-9		16
326	Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. <b>2010</b> , 21, 1395-1403		112
325	A critical need to reconsider cancer trial eligibility requirements. <b>2010</b> , 79, 1-2		1
324	Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. <b>2010</b> , 30, 548-56		57
323	Under-recognized renal insufficiency in hospitalized patients: implications for care. <b>2010</b> , 21, 327-32		12
322	Therapeutic management of breast cancer in the elderly. <b>2011</b> , 12, 945-60		13
321	Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 1125-32	2.2	910
320	Spécificités et recommandations concernant la chimiothérapie chez le sujet âgé: toxicité rénale et cardiaque. <b>2011</b> , 11, 250-258		
319	Pharmacokinetics in Drug Development. <b>2011</b> ,		20
318	Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients. <b>2011</b> , 22, 2073-2079		49
317	Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. <b>2011</b> , 29, 492-4		14
316	[Management of side effects of targeted therapies in renal cancer: nephrological side effects]. <b>2011</b> , 98, S7-S18		1
315	Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. <b>2011</b> , 22, 794-800		22
314	Evaluation of current practice: management of chemotherapy-related toxicities. <b>2011</b> , 22, 919-25		12
313	Dosing modifications of targeted cancer therapies in patients with special needs: evidence and controversies. <b>2012</b> , 81, 58-74		3
312	Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin. <b>2011</b> , 68, 693-701		5

311	Management of hematological malignancies in patients affected by renal failure. <b>2011</b> , 11, 415-32	7
310	Thoracic malignancies, cisplatin and renal function. <b>2011</b> , 37, 760-1	3
309	A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. <b>2011</b> , 25, 525-52	117
308	Pharmacokinetics, Modeling, and Simulation in the Development of Sunitinib Malate: A Case Study. <b>2011</b> , 261-284	
307	Temsirolimus: a safety and efficacy review. <b>2012</b> , 11, 861-79	27
306	Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. <b>2012</b> , 4, 85-101	10
305	[Management of chemotherapy in hemodialysis patients]. <b>2012</b> , 99, 371-80	5
304	[Management of targeted therapies in hemodialysis patients]. <b>2012</b> , 99, 381-8	4
303	Evaluation of glomerular filtration rate estimation by Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease (MDRD) formulae in oncology patients. <b>2012</b> , 23, 1845-53	40
302	[How to evaluate renal function in cancer patients]. <b>2012</b> , 99, 277-83	1
301	[Anticancer drugs management in renal insufficiency patients]. <b>2012</b> , 99, 323-31	3
300	[Risk of cancer in patients following chronic dialysis and kidney graft]. <b>2012</b> , 99, 285-93	3
299	Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors. <b>2012</b> , 5, 359-71	17
298	Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients. <b>2012</b> , 130, 853-8	16
297	Use of cellular electrical impedance sensing to assess in vitro cytotoxicity of anticancer drugs in a human kidney cell nephrotoxicity model. <b>2012</b> , 137, 1343-50	30
296	Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads. <i>Supportive Care in Cancer</i> , <b>2012</b> , 20, 3033-42	3-9 23
295	Importance of monitoring renal function in patients with cancer. <b>2012</b> , 38, 235-40	45
294	Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. <b>2012</b> , 48, 3082-92	404

293	Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations. <b>2012</b> , 38, 815-24		15
292	Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer. <b>2012</b> , 7, 439-46		38
291	[Management of analgesics in cancer patients with renal impairment]. <b>2012</b> , 99, 345-69		2
290	Rein et cancer : une prise en charge transversale. <b>2012</b> , 99, 231		
289	[Renal insufficiency and breast cancer]. <b>2012</b> , 99, 309-15		
288	End stage and chronic kidney disease: associations with renal cancer. <b>2012</b> , 2, 28		49
287	Evaluation of carboplatin dosing in non-small cell lung carcinoma patients using Calvert formula and Cockcroft and Gault equation for glomerular filtration rate estimation. <b>2012</b> , 4, 1072-1076		1
286	Importance of antiresorptive therapies for patients with bone metastases from solid tumors. <b>2012</b> , 4, 287-97		5
285	Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. <b>2012</b> , 30, 1116-20		4
284	Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature review. <i>BMC Nephrology</i> , <b>2013</b> , 14, 84	2.7	11
283	New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism. <b>2013</b> , 26, 163-9		8
282	Considerations regarding the administration of systemic therapy for elderly patients with ovarian cancer. <b>2013</b> , 14, 1-11		4
281	Management of Gynecological Cancers in Older Women. <b>2013</b> ,		1
280	Renal and pulmonary late effects of cancer therapy. <b>2013</b> , 40, 757-73		19
279	Cancer and the kidney: individualizing dosage according to renal function. <b>2013</b> , 24, 2713-4		6
278	[Patient education]. <i>Nephrologie Et Therapeutique</i> , <b>2013</b> , 9, 235-40	0.6	3
277	Bone-targeted therapies for elderly patients with renal cell carcinoma: current and future directions. <b>2013</b> , 30, 877-86		2
276	Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?. <b>2013</b> , 2, 21		21

275	Spffolgen onkologischer Therapie. <b>2013</b> , 19, 1083-1094		
274	Patient and caregiver knowledge and utilization of partial versus radical nephrectomy: results of a national kidney foundation survey to assess educational needs of kidney cancer patients and caregivers. <b>2013</b> , 61, 939-46		5
273	Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: review of the literature and proposal for management changes. <b>2013</b> , 49, 482-91		33
272	[Delayed effects of oncological therapy]. <b>2013</b> , 54, 1221-32		1
271	Are we using oxycodone appropriately? A utilisation review in a UK tertiary care centre. <b>2013</b> , 20, 125-128		4
270	A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. <b>2013</b> , 34, 141-54		61
269	Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose. <b>2013</b> , 24, 2746-52		26
268	Assessment and management of renal impairment in chemotherapy for urogenital cancer. <b>2013</b> , 43, 1055-63		2
267	Comorbid diseases interact with breast cancer to affect mortality in the first year after diagnosis--a Danish nationwide matched cohort study. <i>PLoS ONE</i> , <b>2013</b> , 8, e76013	3.7	35
266	Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer. <b>2014</b> , 48, 1159-1165		20
265	Prevalence of renal insufficiency in elderly cancer patients in a tertiary cancer center. <b>2014</b> , 12, 300-3		7
264	African Americans with cancer pain are more likely to receive an analgesic with toxic metabolite despite clinical risks: a mediation analysis study. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2773-9	2.2	31
263	[Axitinib in metastatic renal carcinomas: update of knowledge about side effects]. <b>2014</b> , 101, 976-88		2
262	How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study. <b>2014</b> , 77, 498-508		8
261	Temsirolimus for advanced renal cell carcinoma. <b>2014</b> , 14, 9-21		19
260	Managing pain in advanced illness. <b>2014</b> , 14, 303-7		2
259	Spffolgen onkologischer Therapie. <b>2014</b> , 9, 50-59		
258	Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. <b>2014</b> , 134, 44-9		20

257	Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. <b>2014</b> , 12, 354-8		20
256	The newer anticoagulants in thrombosis control in cancer patients. <b>2014</b> , 41, 339-45		4
255	Management of venous thromboembolism in cancer patients. <b>2014</b> , 2, 24-36		2
254	Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow?. <b>2014</b> , 36, 420-9		17
253	Dose adjustment of carboplatin in patients on hemodialysis. <b>2014</b> , 31, 848		6
252	Local ablative treatments of oligometastases from head and neck carcinomas. <b>2014</b> , 91, 47-63		48
251	Management of Chronic Kidney Disease. <b>2014</b> ,		1
250	In silico evaluation of gadofosveset pharmacokinetics in different population groups using the Simcyp® simulator platform. <b>2014</b> , 2, 2		8
249	Inappropriate prescribing in patients accessing specialist palliative day care services. <b>2014</b> , 36, 535-43		25
248	Acute kidney injury in the cancer patient. <i>Advances in Chronic Kidney Disease</i> , <b>2014</b> , 21, 64-71	4.7	41
247	Renal function and symptoms/adverse effects in opioid-treated patients with cancer. <b>2015</b> , 59, 1049-59		14
246	Prevalence of Renal Impairment in Palliative Care Inpatients: A Retrospective Analysis. <b>2015</b> , 18, 613-7		2
245	Cancer Survivorship and Models of Survivorship Care: A Review. <b>2015</b> , 38, 627-33		27
244	Individualizing pharmacotherapy in patients with renal impairment: the validity of the Modification of Diet in Renal Disease formula in specific patient populations with a glomerular filtration rate below 60 ml/min. A systematic review. <i>PLoS ONE</i> , <b>2015</b> , 10, e0116403	3.7	9
243	Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States. <b>2015</b> , 4, 713-20		8
242	Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer. <b>2015</b> , 16, e131-40		7
241	Medical anticancer treatment of lung cancer associated with comorbidities: a review. <b>2015</b> , 87, 241-8		5
240	Comparative performances of the new chronic kidney disease epidemiology equations incorporating cystatin C for use in cancer patients. <b>2015</b> , 11, 142-51		12

239	Effects of unidentified renal insufficiency on the safety and efficacy of chemotherapy for metastatic colorectal cancer patients: a prospective, observational study. <i>Supportive Care in Cancer</i> , <b>2015</b> , 23, 1043-8	3.9	16
238	Renal effects of targeted anticancer therapies. <b>2015</b> , 11, 354-70		74
237	Onconeurology. <b>2015</b> ,		
236	Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). <b>2015</b> , 26, 1677-84		52
235	Not All Deaths in CKD Are from a Broken Heart. <b>2015</b> , 26, 2307-8		
234	Cancer and Chronic Kidney Disease. <b>2015</b> , 571-584		1
233	Are the equations for the creatinine-based estimated glomerular filtration rate applicable to the evaluation of renal function in Japanese children and adult patients receiving chemotherapy?. <b>2015</b> , 19, 298-308		3
232	Baseline renal function as a prognostic indicator in patients with newly diagnosed diffuse large B-cell lymphoma. <b>2016</b> , 51, 113-21		10
231	NETosis in Cancer - Platelet-Neutrophil Crosstalk Promotes Tumor-Associated Pathology. <b>2016</b> , 7, 373		44
230	Tumor-Induced NETosis as a Risk Factor for Metastasis and Organ Failure. <b>2016</b> , 76, 4311-5		72
229	Analysis of Risk Factors for Hyponatremia During or Following Chemotherapy in Children With Cancer: A Hospital-based, Retrospective Cohort Study. <b>2016</b> , 38, 443-8		6
228	Renal Function and All-Cause Mortality Risk Among Cancer Patients. <b>2016</b> , 95, e3728		27
227	Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease: a case report. <b>2016</b> , 27, 464-9		1
226	Immune checkpoint inhibitors renal side effects and management. <b>2016</b> , 8, 1417-1425		8
225	Harmonization of Renal Function Assessment Is Needed Throughout the Whole Process of Anticancer Drug Development. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2429-30	2.2	3
224	Antineoplastic Treatment and Renal Injury: An Update on Renal Pathology Due to Cytotoxic and Targeted Therapies. <b>2016</b> , 23, 310-29		20
223	Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer. <b>2016</b> , 15, 837-51		10
222	Cancer-associated thrombosis. <b>2016</b> , 62, 121-58		37



221	LMWH in cancer patients with renal impairment - better than warfarin?. <b>2016</b> , 140 Suppl 1, S160-4		8
220	Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol. <b>2016</b> , 12, 669-80		27
219	Safety of palliative chemotherapy in advanced pancreatic cancer. <b>2016</b> , 15, 947-54		4
218	[Acute kidney injury : A clinical syndrome]. <b>2016</b> , 57, 983-993		3
217	Does comorbidity interact with prostate cancer to increase mortality? A Danish cohort study of 45 326 prostate cancer patients diagnosed during 1995-2011. <b>2016</b> , 55, 611-8		7
216	Deprescribing in advanced illness. <b>2016</b> , 24, 268-271		7
215	Cancer screening and treatment in patients with end-stage renal disease: remaining issues in the field of onco-nephrology. <b>2016</b> , 2,		3
214	A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function. <b>2016</b> , 78, 1185-1197		2
213	Anemia management in cancer patients with chronic kidney disease. <b>2016</b> , 36, 13-19		7
212	Safety of Denosumab Versus Zoledronic Acid in Patients with Bone Metastases: A Meta-Analysis of Randomized Controlled Trials. <b>2016</b> , 39, 453-9		30
211	Evidence for Neurotoxicity Due to Morphine or Hydromorphone Use in Renal Impairment: A Systematic Review. <b>2016</b> , 19, 1179-1187		11
210	Renal insufficiency and cancer treatments. <b>2016</b> , 1, e000091		29
209	Prognostic Value of Pre-operative Renal Insufficiency in Urothelial Carcinoma: A Systematic Review and Meta-Analysis. <b>2016</b> , 6, 35214		25
208	A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment. <b>2016</b> , 42, 494-504		24
207	Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. <b>2016</b> , 16, 222		26
206	Pharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally Ill Adult Patients. <b>2016</b> , 55, 697-709		20
205	Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 699-705	2.2	30
204	Onco-nephrology: a decalogue. <i>Nephrology Dialysis Transplantation</i> , <b>2016</b> , 31, 515-9	4.3	41

203	Contrast-induced nephropathy in patients with active cancer undergoing contrast-enhanced computed tomography. <i>Supportive Care in Cancer</i> , <b>2016</b> , 24, 1011-7	3.9	31
202	Healthcare resource use and costs associated with renal impairment in US patients with bone metastases from solid tumors. <b>2017</b> , 23, 195-202		4
201	Pain prevalence in cancer patients: status quo or opportunities for improvement?. <b>2017</b> , 11, 99-104		38
200	Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice. <i>Oncolmmunology</i> , <b>2017</b> , 6, e1320009	7.2	31
199	Hypoxia as a target for drug combination therapy of liver cancer. <b>2017</b> , 28, 771-780		22
198	Report of two cases of acute cardiac adverse events in patients with colorectal carcinoma receiving oral capecitabine. <b>2017</b> , 28, 801-807		4
197	Early detection of acute cisplatin nephrotoxicity: interest of urinary monitoring of proximal tubular biomarkers. <b>2017</b> , 10, 639-647		14
196	Evaluation of cystatin C in malignancy and comparability of estimates of GFR in oncology patients. <b>2017</b> , 8, 95-104		14
195	Serial renography for evaluation of the impact of capecitabine therapy on renal function: A case report. <b>2017</b> , 96, e6861		2
194	A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions. <b>2017</b> , 28, 677-701		13
193	The use of opioids in cancer patients with renal impairment-a systematic review. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 661-675	3.9	26
192	Association between renal function and chemotherapy-related toxicity in older adults with cancer. <b>2017</b> , 8, 96-101		19
191	A spectroscopic and molecular docking approach on the binding of tinzaparin sodium with human serum albumin. <b>2017</b> , 1127, 283-288		52
190	Hematologists and nephrologists working together: moving forward with a new integrated care model for blood-related malignancies?. <b>2017</b> , 52, 218-219		1
189	Assessment of renal function in geriatric palliative care patients - comparison of creatinine-based estimation equations. <b>2017</b> , 12, 977-983		5
188	Considering renal risk while managing cancer. <b>2017</b> , 9, 167-178		6
187	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3753-3759	2.2	92
186	Prevalence and mortality of chronic kidney disease in lymphoma patients: A large retrospective cohort study. <b>2018</b> , 97, e9615		5

185	Assessment of Kidney Function in Patients With Cancer. <i>Advances in Chronic Kidney Disease</i> , <b>2018</b> , 25, 49-56	4.7	22
184	Evaluation of chronic kidney disease in cancer patients: is there a preferred estimation formula?. <b>2018</b> , 48, 1382-1388		3
183	Évaluation de la polymédication des patients âgés atteints de cancers bronchiques. <b>2018</b> , 53, 81-86		
182	Ten Tips Nephrologists Wish the Palliative Care Team Knew About Caring for Patients with Kidney Disease. <b>2018</b> , 21, 546-551		5
181	Acute kidney injury in critically ill patients with solid tumours. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, 1997-2005	4.3	19
180	Microscopic hematuria is a risk factor of incident chronic kidney disease in the Korean general population: a community-based prospective cohort study. <b>2018</b> , 111, 389-397		2
179	Incidence and characteristics of chronic renal replacement therapy in patients with cancer: data from kidney and cancer registries in Basse-Normandie. <i>Journal of Nephrology</i> , <b>2018</b> , 31, 111-118	4.8	2
178	Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. <b>2018</b> , 73, 40-50		69
177	Survival of patients with cancer starting chronic dialysis: Data from kidney and cancer registries in lower Normandy. <b>2018</b> , 23, 1125-1130		5
176	Dual-layer DECT for multiphasic hepatic CT with 50 percent iodine load: a matched-pair comparison with a 120 kVp protocol. <b>2018</b> , 28, 1719-1730		28
175	Management of untreated advanced stage follicular lymphoma: Role of patient discernment. <b>2018</b> , 31, 23-30		1
174	Start using a checklist, PRONTO: Recommendation for a standard review process for chemotherapy orders. <b>2018</b> , 24, 609-616		3
173	Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial. <b>2018</b> , 233, 2572-2580		9
172	Opening an onconeurology clinic: recommendations and basic requirements. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, 1503-1510	4.3	26
171	Imprecise Kidney Function Thresholds in Cancer Clinical Trials and the Potential for Harm. <b>2018</b> , 2, pky060		4
170	Thrombosis and kidney disease in cancer: comorbidities defining a very high risk patient: A position paper from the Cancer & the Kidney International Network. <i>Journal of Onco-Nephrology</i> , <b>2018</b> , 2, 37-49	0.2	1
169	Assessment of renal function in Japanese children with malignancies using serum cystatin C. <b>2018</b> , 65, 231-235		2
168	Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities. <b>2018</b> , 17, 553-572		4

167	Carboplatin Dosing Accuracy by Estimation of Glomerular Filtration versus Creatinuria in Cancer Patients. <b>2018</b> , 63, 137-142	4
166	Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review. <b>2018</b> , 74, 1365-1376	12
165	Douleurs, insuffisance rñale chronique et opioïdes : lesquels choisir ? Comment adapter le traitement?. <b>2018</b> , 19, 133-138	
164	Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review. <b>2018</b> , 18, 311	0
163	Representation of Patients With Chronic Kidney Disease in Trials of Cancer Therapy. <b>2018</b> , 319, 2437-2439	26
162	Glomerular Filtration Rate in Patients with Multiple Sclerosis Undergoing Stem Cell Transplantation and Treated with Cyclophosphamide. <b>2019</b> , 50, 42-46	3
161	Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer. <b>2019</b> , 21, 249-258	4
160	Magnetic Resonance Angiography in Pulmonary Embolism: A Review. <b>2019</b> , 48, 586-591	
159	Individualized Treatment Analysis Of Breast Cancer With Chronic Renal Failure. <b>2019</b> , 12, 7767-7772	1
158	Independent Associations Between Glomerular Filtration Rate and Serum Bilirubin Level and Early Mortality in Acute Myeloid Leukemia. <b>2019</b> , 19, e633-e635	
157	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. <b>2019</b> , 96, 555-567	25
156	Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa' Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. <b>2019</b> , 140, 39-51	7
155	Ultra-low dose contrast CT pulmonary angiography in oncology patients using a high-pitch helical dual-source technology. <b>2019</b> , 25, 195-203	7
154	Epidemiology of acute kidney injury and associated factors among patients with malignancy: Analysis of hospital inpatient database in Shanghai, China. <i>Journal of Onco-Nephrology</i> , <b>2019</b> , 3, 39-48	0.2 3
153	Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week. <b>2019</b> , 73, 1336-1349	56
152	Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing. <b>2019</b> , 14, 587-595	29
151	Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <b>2019</b> , 20, e200-e207	34
150	Cancer Survivorship. <b>2019</b> , 380, 1380-1381	6

149	Interdigital sensing system for detection of levels of creatinine from the samples. <b>2019</b> ,		6
148	Highly selective Molecularly Imprinted Polymer for creatinine detection. <b>2019</b> ,		6
147	Agreement and Precision Analyses of Various Estimated Glomerular Filtration Rate Formulae in Cancer Patients. <b>2019</b> , 9, 19356		15
146	Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?. <b>2019</b> , 36, 1-11		5
145	Hypertension prevalence in early breast cancer patients undergoing primary surgery. <b>2019</b> , 64, 32-36		3
144	Both Race and Insurance Type Independently Predict the Selection of Oral Opioids Prescribed to Cancer Outpatients. <b>2020</b> , 21, 65-71		8
143	Cancer and Chronic Kidney Disease. <b>2020</b> , 899-917		1
142	Long-term survival and renal dysfunction in a patient with recurrent colorectal cancer treated with Bevacizumab. <b>2020</b> , 13, 316-319		4
141	Conventional chemotherapy. <b>2020</b> , 127-153.e11		1
140	Improving Cancer Care for Patients With Chronic Kidney Disease. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 188-192	2.2	7
139	Safe Use of Opioids in Chronic Kidney Disease and Hemodialysis Patients: Tips and Tricks for Non-Pain Specialists. <b>2020</b> , 16, 821-837		2
138	The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia. <b>2020</b> , 17, 365-383		13
137	Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency. <b>2021</b> , 27, 1665-1673		
136	The basics of onco-nephrology in the renal clinic. <i>Journal of Nephrology</i> , <b>2020</b> , 33, 1143-1149	4.8	
135	Lymphoma survivors have an increased long-term risk of chronic kidney disease. <b>2020</b> , 61, 2923-2930		1
134	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. <b>2020</b> , 98, 1108-1119		10
133	Molecularly Imprinted Polymer-based detection of creatinine towards smart sensing. <b>2020</b> , 3, e10133		7
132	Decreased Preoperative Estimated Glomerular Filtration Rate Was Related With Poor Prognosis of NSCLC Patients. <b>2020</b> , 19, 1533033820952355		

131	Prediction models for acute kidney injury in patients with gastrointestinal cancers: a real-world study based on Bayesian networks. <b>2020</b> , 42, 869-876		3
130	Use of Alfentanil in Palliative Care. <b>2020</b> , 8,		
129	Perspectives From an Onconephrology Interest Group: Conference Report. <b>2020</b> , 7, 2054358120962589		
128	Onko-Nephrologie. <b>2020</b> ,		
127	Image quality in dual-source multiphasic dynamic computed tomography of the abdomen: evaluating the effects of a low tube voltage (70 kVp) in combination with contrast dose reduction. <b>2020</b> , 45, 3755-3762		2
126	How to determine kidney function in cancer patients?. <b>2020</b> , 132, 141-149		11
125	Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials. <i>Nephrology Dialysis Transplantation</i> , <b>2020</b> ,	4-3	1
124	Prevention and treatment of venous thromboembolism in cancer patients. <b>2020</b> , 45, 652-658		1
123	GFR Measurement and Chemotherapy Dosing in Patients with Kidney Disease and Cancer.. <b>2020</b> , 1, 141-150		4
122	Limitations of Systemic Oncological Therapy in Breast Cancer Patients with Chronic Kidney Disease. <b>2020</b> , 2020, 7267083		5
121	How to assess kidney function in oncology patients. <b>2020</b> , 97, 894-903		5
120	Renal Replacement Therapy in Patients With Stage IV Cancer Admitted to the Intensive Care Unit With Acute Kidney Injury at a Comprehensive Cancer Center Was Not Associated With Survival. <b>2020</b> , 37, 707-715		2
119	Renal Function Assessment Gap in Clinical Practice: An Awkward Truth. <b>2020</b> , 45, 166-179		5
118	Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group. <b>2020</b> , 21, 295-307		3
117	Chronic kidney disease as a complication of cancer, with special focus on kidney and urothelial tumors. <b>2020</b> , 299-306.e1		
116	Administration of iodinated contrast: What is the risk in cancer patients?. <b>2021</b> , 30, e13351		0
115	Exploring the knowledge gap of immune checkpoint inhibitors in chronic renal failure: A systematic review of the literature. <b>2021</b> , 157, 103169		5
114	Concomitant weekly cisplatin-based chemoradiotherapy in head and neck cancer: the value of a second measured glomerular filtration rate during treatment. <b>2021</b> , 94, 20200717		0

113	How to use dialysis wisely in cancer patients?. <i>Journal of Onco-Nephrology</i> , <b>2021</b> , 5, 79-86	0.2
112	Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. <b>2021</b> , 12, 235-238	3
111	Onconeurology: The intersections between the kidney and cancer. <b>2021</b> , 71, 47-77	27
110	Plasmacytoid dendritic cells promote acute kidney injury by producing interferon- $\beta$ . <b>2021</b> , 18, 219-229	3
109	Initiation and termination of dialysis in older patients with advanced cancer: providing guidance in a complicated situation. <b>2021</b> , 2, e42-e52	1
108	Interdigital Sensing System for Kidney Health Monitoring. <b>2021</b> , 267-309	5
107	Development of MEMS Sensor for Detection of Creatinine using MIP Based Approach -A Tutorial Paper. <b>2021</b> , 1-1	3
106	Nephrology. <b>2021</b> , 397-405	
105	Spectrum of cancer patients receiving renal biopsy. <b>2021</b> , 121, 152-152	
104	Favorable survival with combined treatment in a metastatic breast cancer patient undergoing hemodialysis: A case report. <b>2021</b> , 79, 206-209	1
103	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group. <b>2021</b> , 27, 2416-2423	7
102	Drug dosing in cancer patients with decreased kidney function: A practical approach. <b>2021</b> , 93, 102139	1
101	Noninvasive assessment of radiation-induced renal injury in mice. <b>2021</b> , 97, 664-674	1
100	Monographic consultation of onconeurology. Rationale and implementation. <b>2021</b> , 41, 154-164	
99	Monographic consultation of onconeurology. Rationale and implementation. <b>2021</b> , 41, 154-164	1
98	Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3 5
97	Nephrotoxicity of Anti-Angiogenic Therapies. <b>2021</b> , 11,	5
96	Physiologically-based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment. <b>2021</b> , 42, 263-284	1

95	2. Clinical Pharmacology in Patients with Cancer as a Comorbidity. <b>2021</b> , 52, 70-74		
94	Treatment of venous thromboembolism in cancer patients: The dark side of the moon. <b>2021</b> , 96, 102190		3
93	Primary Thromboprophylaxis in Patients with Malignancies: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (ÖHO). <b>2021</b> , 13,		2
92	Healthcare utilization and spending among older patients diagnosed with Non-Hodgkin lymphoma. <b>2021</b> , 12, 1225-1232		0
91	The effect of a Clinical Decision Support System on the frequency of dose adjustments of anticancer drugs in case of renal or hepatic dysfunction. <b>2021</b> , 10781552211019453		
90	A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. <b>2021</b> , 88, 485-497		1
89	Pre-existing chronic kidney disease and hypertension increased the risk of cardiotoxicity among colorectal cancer patients treated with anticancer drugs. <b>2021</b> , 84, 877-884		0
88	Kidney-Protector Lipidic Cilastatin Derivatives as Structure-Directing Agents for the Synthesis of Mesoporous Silica Nanoparticles for Drug Delivery. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
87	Haemodialysed patient with lung cancer in the COVID-19 era: a clinical challenge. <b>2021</b> , 14,		1
86	Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants. <b>2021</b> , 22, 1333-1340		5
85	The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study. <b>2021</b> , 110, 3507-3519		1
84	Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. <b>2021</b> , 157, 50-58		1
83	Opioid Use in the Nondialysis Chronic Kidney Disease Population. <b>2021</b> , 41, 33-41		
82	Biological aspects of aging that influence response to anticancer treatments. <b>2021</b> , 15, 29-38		0
81	Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity. <b>2021</b> , 11, 750		6
80	Chronic Conditions and Cancer at the End of Life. <b>2016</b> , 455-475		1
79	Anticoagulation in Cancer Patients: a Summary of Pitfalls to Avoid. <b>2019</b> , 21, 18		14
78	A physiologically based pharmacokinetic - pharmacodynamic modelling approach to predict incidence of neutropenia as a result of drug-drug interactions of paclitaxel in cancer patients. <b>2020</b> , 150, 105355		3



77	Unrecognized renal insufficiency and chemotherapy-associated adverse effects among breast cancer patients. <b>2012</b> , 23, 991-5		7
76	Clinically significant estimated glomerular filtration rate decline is common in patients receiving immune checkpoint inhibitors: implications for long-term cancer survivors.		0
75	Diagnosis and therapy in cancer-associated thromboembolism – what about guideline recommendations?. <b>2015</b> , 44, 299-303		1
74	Incidence of contrast-induced acute kidney injury (CI-AKI) in high-risk oncology patients undergoing contrast-enhanced CT with a reduced dose of the iso-osmolar iodinated contrast medium iodixanol. <i>PLoS ONE</i> , <b>2020</b> , 15, e0233433	3.7	6
73	Acute kidney injury in cancer patients. <b>2020</b> , 66Suppl 1, s25-s30		6
72	Cancer and the kidney: dangereux liaisons or price paid for the progress in medicine?. <b>2017</b> , 8, 66601-66619		12
71	Detecting Lifestyle Risk Factors for Chronic Kidney Disease With Comorbidities: Association Rule Mining Analysis of Web-Based Survey Data. <b>2019</b> , 21, e14204		5
70	Chemotherapy in the elderly: are their needs being met?. <b>2009</b> , 6, 893-902		2
69	Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. <b>2011</b> , 17, 3510-7		18
68	Evaluation of Basal Renal Function in Treatment-naïve Patients with Malignancy and Comparison with Age Matched Healthy Control. <b>2016</b> , 15, 148-52		1
67	Risk factors for acute kidney injury after partial hepatectomy. <b>2017</b> , 9, 815-822		13
66	Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury. <b>2015</b> , 16, 407-10		11
65	Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis. <i>Supportive Care in Cancer</i> , <b>2021</b> , 1	3.9	1
64	Magnesium Salts in a Cancer Patient: Pathobiology and Protective Functions. <b>2013</b> , 159-180		
63	Ovarian Cancer: Primary Chemotherapy. <b>2013</b> , 171-181		
62	Traitement personnalisé selon la fonction rénale. <b>2013</b> , 17-27		
61	Chronic Kidney Disease and Cancer. <b>2014</b> , 407-415		
60	Spätfolgen onkologischer Therapie.		

59	Spffolgen onkologischer Therapie. <b>2015</b> , 115-124		
58	Chronic Kidney Disease (CKD) in Cancer Patients. <b>2015</b> , 25-46		
57	Impact of Comorbidity on Treatment Decision Making and Outcomes. <b>2016</b> , 131-158		
56	Lack of usefulness of computed tomography for surveillance in patients with aggressive non-Hodgkin lymphoma. <i>PLoS ONE</i> , <b>2018</b> , 13, e0192656	3.7	1
55	Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience. <b>2018</b> , 10, e3634		
54	Principles of Chemotherapy in Older Adults. <b>2019</b> , 1-20		
53	Detecting Lifestyle Risk Factors for Chronic Kidney Disease With Comorbidities: Association Rule Mining Analysis of Web-Based Survey Data (Preprint).		
52	Chronische Niereninsuffizienz und onkologische Erkrankungen. <b>2020</b> , 31-44		
51	Concomitant Drug Treatment and Elimination in the RCC-affected Kidneys: Can We Kill Two Birds with One Stone?. <b>2020</b> , 21, 1009-1021		1
50	Renal Toxicity. <i>Advances in Experimental Medicine and Biology</i> , <b>2020</b> , 1244, 287-293	3.6	
49	Cancer et fonction rñale. <b>2020</b> , 109-114.e3		
48	Principles of Chemotherapy in Older Adults. <b>2020</b> , 861-880		
47	Potassium in Solid Cancers.		
46	Chronic kidney disease and cancer: a troubling connection. <i>Journal of Nephrology</i> , <b>2010</b> , 23, 253-62	4.8	106
45	Management of nephrotoxicity of chemotherapy and targeted agents: 2020. <i>American Journal of Cancer Research</i> , <b>2020</b> , 10, 4151-4164	4.4	3
44	Niere und Elektrolyte, Osteoprotektion. <b>2022</b> , 92-99		
43	Role of Cell-Free DNA and Deoxyribonucleases in Tumor Progression. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
42	[Renal toxicity of anticancer drugs]. <i>Nephrologie Et Therapeutique</i> , <b>2021</b> , 17, 553-563	0.6	1

41	Renal Toxicity.. <i>Advances in Experimental Medicine and Biology</i> , <b>2021</b> , 1342, 389-397	3.6	
40	Chronic kidney disease and its health-related factors: a case-control study.. <i>BMC Nephrology</i> , <b>2022</b> , 23, 24	2.7	0
39	Agreement between serum estimates of glomerular filtration rate (GFR) and a reference standard of radioisotopic GFR in children with cancer.. <i>Pediatric Radiology</i> , <b>2022</b> , 1	2.8	
38	Breast Cancer with Associated Problems. <b>2022</b> , 519-537		
37	The 'other' big complication: how chronic kidney disease impacts on cancer risks and outcomes.. <i>Nephrology Dialysis Transplantation</i> , <b>2022</b> ,	4.3	0
36	Non-immunological Causes of Tubulointerstitial Disease. <b>2022</b> , 185-197		
35	Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102492	2.2	4
34	Neutrophil extracellular traps promote cancer-associated inflammation and myocardial stress.. <i>Oncolmmunology</i> , <b>2022</b> , 11, 2049487	7.2	0
33	Impact of perioperative blood transfusions on postoperative renal function and survival after resection of colorectal liver metastases.. <i>World Journal of Surgical Oncology</i> , <b>2022</b> , 20, 100	3.4	0
32	Cancer thrombosis: Narrative review. <i>Cancer Research Statistics and Treatment</i> , <b>2020</b> , 3, 501	0.3	1
31	Venous Thromboembolism In Cancer Patients: "From Evidence to Care".. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2022</b> , 28, 10760296221098717	3.3	
30	Nephrotoxicity in cancer treatment: An update. <i>Advances in Cancer Research</i> , <b>2022</b> ,	5.9	0
29	Oncology and the Kidney. <b>2022</b> , 813-826		
28	Improving cancer care for patients with chronic kidney disease: the need for changes in clinical trials. <i>Kidney International Reports</i> , <b>2022</b> ,	4.1	0
27	Development and organization of onco-nephrology in France, comment on "The path toward the creation of the American Society of Onco-Nephrology (ASON)" <i>Journal of Onco-Nephrology</i> , 239936932211064	0.2	0
26	Cancer Drug Dosing in Chronic Kidney Disease and Dialysis. <i>Advances in Chronic Kidney Disease</i> , <b>2022</b> , 29, 208-216.e1	4.7	
25	Chronic kidney disease in cancer patients, the analysis of a large oncology database from Eastern Europe. <i>PLoS ONE</i> , <b>2022</b> , 17, e0265930	3.7	1
24	Prognostic factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer: a retrospective study. <i>Supportive Care in Cancer</i> ,	3.9	

23	Onco-nephrology: Physicians' Expectations About a New Subspecialty. <i>Journal of Cancer Education</i> , 1.8	
22	Serum cystatin C level can be used to estimate GFR in patients with solid tumors: Moderator Commentary. <i>Journal of Onco-Nephrology</i> , 239936932211149	0.2
21	Carboplatin dose calculations for patients with lung cancer: significant dose differences found depending on dosing equation choice. <b>2022</b> , 22,	0
20	Neutrophil extracellular traps in the pathology of cancer and other inflammatory diseases.	1
19	Maintenance avelumab in a patient with metastatic urothelial carcinoma on hemodialysis: A case report. <b>2022</b> , 100189	0
18	Estimating renal insufficiency in breast cancer patients using ultrasound determined resistive index: A cross-sectional study of a Nigerian Cohort. <b>2022</b> , 3, 8	0
17	Outcomes of CD19 targeted CAR T-cell Therapy for Patients with Reduced Renal Function Including Dialysis. <b>2022</b> ,	0
16	Chronic Kidney Disease Prevalence in Patients with Colorectal Cancer Undergoing Surgery. <b>2022</b> , 12, 2137	0
15	IVIVE of Bexarotene Metabolism in The Presence of Chronic Kidney Disease and Acute Kidney Injury in Rat Using PBPK Modeling and Extrapolation to Human.	0
14	Dose Adjustment of Poly (ADP-Ribose) Polymerase Inhibitors in Patients with Hepatic or Renal Impairment. Volume 16, 3947-3955	0
13	Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer. <b>2022</b> , 7, 100633	0
12	Indoxyl Sulfate Promotes Metastatic Characteristics of Ovarian Cancer Cells via Aryl Hydrocarbon Receptor-Mediated Downregulation of the Mas Receptor. <b>2023</b> , 100025	0
11	Inclusion of Participants with CKD and Other Kidney-Related Considerations during Clinical Drug Development. <b>2023</b> , 18, 455-464	0
10	Activation/deactivation of anticancer drugs by CYP3A4: influencing factors for personalized cancer therapy. DMD-MR-2022-001131	0
9	Lung cancer-kidney cross talk induces kidney injury, interstitial fibrosis, and enhances cisplatin-induced nephrotoxicity. <b>2023</b> , 324, F287-F300	0
8	Analysis of the Incidence of Type 2 Diabetes, Requirement of Insulin Treatment, and Diabetes-Related Complications among Patients with Cancer. <b>2023</b> , 15, 1094	0
7	Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study.	0
6	Association between rapid renal function deterioration and cancer mortality in the elderly: A retrospective cohort study.	0

- 5 Time to Abandon Renalism. **2023**, 18, 419-420 ○
- 4 The Onco-Nephrology Field: The Role of Personalized Chemotherapy to Prevent Kidney Damage. **2023**, 15, 2254 ○
- 3 Onco-Nephrology. **2023**, ○
- 2 Glomerular Filtration Rate Measurement and Chemotherapy Dosing. **2022**, 42, 151340 ○
- 1 Kidney Disease Patient Representation in Trials of Combination Therapy With VEGF-Signaling Pathway Inhibitors and Immune Checkpoint Inhibitors: A Systematic Review. **2023**, 100672 ○